Abstract:Background: Spontaneous reporting of adverse drug events (ADEs) has long been the cornerstone of pharmacovigilance. Medical institutions in China have been a major source of ADE case reports, but the proportion of reports from tertiary hospitals is low due to the serious underreporting of case reports. The same problem existed in the Second Affiliated Hospital of Zhejiang University School of Medicine (SAHZU). Objective: In order to increase the number of ADE reports and promote hospital pharmacovigilance, SAHZU's clinical pharmacists established a pharmacist-led ADE management model. The aim of this paper is to introduce this management model and explore the advantages and disadvantages of the model. Methods: Pharmacist-led ADE management model was gradually formed from 2015 to 2017 in the SAHZU. This "pharmacist-led" model is reflected not only in the fact that clinical pharmacists are the main reporters of SAHZU's ADEs but also in that they are the main groups to analyze and manage ADE and drug errors. The sources of ADEs reported by clinical pharmacists mainly include pharmacy rounds, ADE-related pharmacist consultations, centralized monitoring, ADE warning signal analysis, newly introduced drug evaluations, and drug safety research. Results: A total of 533 ADEs were reported by SAHZU to China's spontaneous reporting system (SRS) in 2017, while the data in 2012 was 177, with an increase by 201%. In 2012, the proportion of "new" and "serious" reports was 16.4%. The proportions during the period from 2015 to 2017 were 41.4%, 60.8%, and 52.2%, respectively, which were statistically significant compared with the proportion in 2012. The proportion of ADEs reported by clinical pharmacists during the period from 2014 to 2017 were 51.5%, 57.3%, 68.8%, and 90.8%, respectively, which were statistically significant compared with the proportion in 2013 (P<0.05). There was a correlation between the proportions of severe ADEs and the proportion of ADEs reported by clinical pharmacists (r=0.873, P=0.023). Four hundred eighty four ADE cases reported by clinical pharmacists to China's SRS in 2017 were mainly found in rounds of clinical pharmacists (74.17% [359/484]). Conclusion: The pharmacist-led pharmacovigilance working model significantly increased the quantity and quality of ADE reporting in SAHZU and promoted pharmacovigilance. This model is worth developing in Chinese tertiary hospitals and the following hospitals, where the physicians working there spend little time and energy on ADE reporting or the cost of physicians is high, while the clinical pharmacist team has strong professional skills.

Analysis and research about the management of ethical post approval review in human subject research

Practical exploration and research on improving the efficiency of ethical review

Design and Implementation of Information Management System for Clinical Research Ethics Review in Large General Hospitals

Analysis of a Pharmacist-Led Adverse Drug Event Management Model for Pharmacovigilance in an Academic Medical Center Hospital in China

Application and exploration of ethics review platform

Common Problems in the Ethical Review of Clinical Trial Protocols and the Countermeasures

A Brief Discussion on the Continuing Review Policy Construction of Institutional Review Board

Interprestation of the key review points of human genetic resources application

Survey and Analysis of Clinical Researchers' Knowledge, Attitude and Practice (KAP) about Ethical Review

Ethics Committee' s Management of Noncompliance/Violation or Protocol Deviation Report in Clinical Research

Post-approval process: A challenge for ethics committees

Ethics approval: responsibilities of journal editors, authors and research ethics committees

Ethical management of human clinical research in the age of big data

Analysis and Countermeasures of Demands Investigation on Ethical Review Knowledge Training among Clinical Investigators

Analysis and discussion on the subject complaint in clinical drug trials

Study on the Standardization of Initial Ethical Review of Drug Clinical Trial

Discussion of the Site Visit Strategy of Institutional Review Board

Review of the Latest Revision of Common Rule in the United States

Sustainable Development of Biomedical Research Ethics

Ethics Management of Clinical Research Application and Self-Evaluation of Ethics from Applicant in 2007 Capital Medical Development Scientific Research Fund

[Consensus on Collaborative Ethical Review of Multi-Center Clinical Trials of New Drugs of Traditional Chinese Medicine (version 1.0)].